YiChang HEC ChangJiang Pharmaceutical Co., Ltd. provided earnings guidance for the year ended December 31, 2016. The board of directors of the company announced that, based on the currently available unaudited management accounts of the Group and the preliminary assessment by the company's management, it is expected that the group will record an increase in profit attributable to equity shareholders of not less than 40% for the year ended 31 December 2016, as compared to the year ended 31 December 2015. The expected growth in profit attributable to equity shareholders is primarily attributed to: the significant increase in the sales volume of Kewei, one of the company's key products; and (ii) the continuous improvement of the academic promotion activities of the Company.